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Abstract
The androgen receptor (AR) is a member of the steroid receptor superfamily that regulates
gene expression in a ligand-dependent manner. The NTD of the AR plays a key role in AR
transactivation including androgen-independent activation of the AR in castration-resistant
prostate cancer (CRPC) cells. We recently reported that amino acids (a.a.) 50-250 of the
NTD are capable of modulating AR nucleocytoplasmic trafficking. To further explore the
mechanism associated with a.a. 50-250, GFP pull-down assays were performed in C4-2
CRPC cells transfected with GFP tagged a.a. 50-250 of the AR. Mass spectrometry analy-
sis of the pulled down proteins identified poly (A) binding protein cytoplasmic 1 (PABPC1)
interaction with this region of the AR. In silicoanalysis of gene expression data revealed
PABPC1 up-regulation in prostate cancer tissue specimens and this up-regulation corre-
lates to increased disease recurrence. Co-immunoprecipitation assays confirmed the asso-
ciation of PABPC1 with a.a. 50-250 of the NTD of the AR. Knockdown of PABPC1
decreased nuclear AR protein levels and inhibited androgen activation of the AR target PSA
in LNCaP and C4-2 cells. Additionally, knockdown of PABPC1 inhibited transactivation of
the PSA promoter by NAR (AR lacking the LBD) and attenuated proliferation of AR-positive
prostate cancer cells. These findings suggest that PABPC1 is a novel co-regulator of the
AR and may be a potential target for blocking activation of the AR in CRPC.
Introduction
Prostate cancer is the second leading cause of cancer death in the United States killing almost
30,000 men annually [1]. Localized prostate cancer that is confined entirely to the prostate
gland is curable, but when the cancer has spread to distant tissues, organs, and lymph nodes,
the five year survival rate is only 28% [1]. Since androgens are known to participate in the
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progression of prostate cancer, the first line of therapy for patients with metastatic prostate
cancer is usually androgen deprivation therapy (ADT). ADT involves using drugs such as
lupron and bicalutamide that target androgen receptor (AR) signaling through lowering serum
testosterone or blocking the binding of androgens to the AR [2–6]. However, most patients
eventually relapse and the cancer becomes resistant to hormone therapy, a condition known as
castration-resistant or–recurrent prostate cancer (CRPC). Abiraterone and enzalutamide are
newly approved drugs for CRPC patients; although, patients will still eventually relapse and the
overall survival is prolonged only ~4–5 months after treatment with the AR signaling becom-
ing active in most of these relapsed tumors [7,8]. Therefore, a detailed understanding of the
mechanisms regulating AR function may lead to novel approaches targeting the AR in CRPC
as well as in CRPC relapsed after treatment with abiraterone and enzalutamide.
The AR is a member of the steroid receptor superfamily that regulates gene expression in a
ligand-dependent manner. It plays a vital role in all stages of prostate cancer development and
progression, including CRPC. The N-terminal domain (NTD) of the AR is the least conserved of
the four domains of the receptor and does not have an ordered structure [9,10]. It contains the
activation function 1 (AF1) element that is crucial for AR transactivational activity [11]. AF1 is
located between amino acids 101 and 370 and is required for full ligand activated transcriptional
activity. Additionally, activation function 5 (AF5) which is located between residues 360–485 is
responsible for AR constitutive activity in the absence of ligand [11]. The NTD of the AR plays a
key role in AR transactivation including androgen-independent activation of the AR in CRPC
cells. Previous studies by our group determined that the NTD of the AR contains a region, a.a.
50–250, that can regulate its nucleocytoplasmic localization [12]. However, the mechanism by
which the a.a. 50–250 region modulates AR subcellular localization is not clear. Binding partners
of this region are likely to play a role in modulating AR subcellular localization and function.
Thus, identification of binding partners of a.a. 50–250 of the NTD will be crucial to mechanistic
studies associated with this region, which may lead to the design of novel therapies.
In the present study, we explored potential mechanisms involved in the modulation of AR
subcellular localization and function by the a.a. 50–250 region of the NTD using immunopre-
cipitation coupled with proteomics. This led to the identification of poly (A) binding protein
cytoplasmic 1 (PABPC1) as a binding partner of the region in the NTD capable of promoting
AR cytoplasmic localization. PABPC1 is known to bind to the 3’ poly (A) tail of eukaryotic
mRNA via RNA recognition motifs [13]. It is involved in shortening of the poly (A) tail and
translation initiation [13], and is capable of shuttling between the nucleus and the cytoplasm
[14]. Further functional characterization suggests that PABPC1 plays an important role in
modulating AR nucleocytoplasmic localization and function in prostate cancer cells.
Methods
Cell lines and plasmids
LNCaP, 22Rv1, and PC3 cells were purchased from American Type Culture Collection
(Manassas, VA). C4-2 cells were obtained from Dr. Leland Chung (Cedars Sinai Medical Cen-
ter, Los Angeles, CA). All cells were maintained in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS), 1% L-glutamine, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin (Invitrogen, Grand Island, NY). Cells were grown at 37°C in the presence of 5% CO2 in
a humidified incubator. For androgen induction, cells were grown in 5% charcoal stripped FBS
RPMI for 24 hours followed by addition of R1881 (Perkin Elmer, Waltham, MA) for an addi-
tional 24 hours.
The expression vector pEGFP-C1 (Clontech, Mountain View, CA) was used to generate
fusion protein constructs with GFP at the N terminus of AR and various AR mutants as
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described [12]. The PSA6.1 luciferase reporter construct was generously provided by Dr. Mar-
ianne Sadar [15]. The pRL-CMV renilla luciferase reporter construct was purchased from Pro-
mega (Sunnyvale, CA).
GFP pull-down assay
C4-2 cells were transiently transfected with indicated AR deletion constructs tagged with GFP
using Polyjet transfection reagent (SignaGen Laboratories, Rockville, MD) in 10% FBS RPMI
media. Cells were lysed with NP-40 lysis buffer 48 hours after transfection. GFP pull-down
assays were performed using anti-GFP tagged agarose beads (20μl) (MBL International,
Woburn, MA) followed by SDS-PAGE. SDS-PAGE gels were stained with coomassie blue to
visualize banding patterns in immunoprecipitation compared with GFP control immunopre-
cipitation. Gel bands that were uniquely pulled down by a.a. 50–250 of the NTD of the AR
(GFP-AR50-250) were excised and sent for analysis by mass spectrometry at the Cancer Bio-
markers Facility (CBF) of University of Pittsburgh Cancer Institute (UPCI) (Pittsburgh, PA).
Mass spectrometry
Gel bands were excised and destained, disulfides were reduced with Tris (2-carboxyethyl)
phosphine hydrochloride (TCEP) (Sigma Aldrich, St Louis, MO), and sulfhydryls were alkyl-
ated with iodoacetamide (Sigma Aldrich, St Louis, MO) as previously described [16]. Gel plugs
were digested overnight with 13 ng/μl trypsin (Promega, Madison, WI) at 37°C. Peptides were
extracted with 1:2 (vol/vol) 5% formic acid/acetonitrile for mass spectrometric analysis.
MALDI TOF/TOF analysis was done on a 4800 MALDI-TOF/TOF analyzer (ABSciex, Foster
City, CA). MALDI TOF/TOF data was analyzed for protein identification with ABSciex Pro-
tein Pilot 3.0 using Mascot (version 2.1.0). Searches used the IPI_human_3.68 human (87061
sequences; 35160944 residues) protein database. The search parameters used trypsin as the
proteolytic enzyme with one missed cleavage permitted, carbamidomethylation of cysteines
and oxidation of methionines as variable modifications, and mass tolerance of 50ppm and 0.4
Da for precursor ions and fragment ions, respectively. Protein score is -10Log(P), where P is
the probability that the observed match is a random event. Protein scores were derived from
ion scores as a non-probabilistic basis for ranking protein hits. Protein scores greater than 62
were considered to be significant (p<0.05).
Co-immunoprecipitation
C4-2 cells were transiently transfected with AR deletion constructs tagged with GFP using
Polyjet transfection reagent (SignaGen Laboratories, Rockville, MD). C4-2 cells were also stably
transfected with GFP or GFP-tagged AR deletion constructs in the presence of G418. GFP
pull-down assays were performed using anti-GFP tagged agarose beads (MBL International,
Woburn, MA) followed by Western blot analysis using antibodies specific for PABPC1 (F-2)
(Santa Cruz Biotechnology, Dallas, TX) and GFP (Torrey Pines Biolabs, Inc., Houston, TX).
siRNA knockdown
Control siRNA (sc-37007) and siRNA oligos specific for PABPC1 (sc-108012) were purchased
from Santa Cruz Biotechnology (Dallas, TX) and transfected for knock down of PABPC1. Cells
were transfected in OPTI-MEMmedia (Life Technologies, Grand Island, NY) using Lipofecta-
mine 2000 (Life Technologies, Grand Island, NY) according to the manufacturer’s instructions
and harvested 72 hours after transfection in RIPA buffer for analysis by Western blot using
antibodies specific for PABPC1 (F-2), PSA (C-19) and GAPDH (FL-335) (all purchased from
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Santa Cruz Biotechnology, Dallas, TX). GAPDH was included as a loading control. For locali-
zation of the AR, C4-2 cells were seeded into 10cm2 dishes followed by knockdown of
PABPC1. Nuclear and cytoplasmic fractions were prepared using the NE-PER Nuclear and
Cytoplasmic Extraction kit from Thermo Fisher Scientific following the manufacturer’s recom-
mendations (Rockford, IL). GAPDH and Lamin A/C (Genscript, Piscataway, NJ) were used as
loading controls. For mRNA expression following knockdown, cells were assayed as described
below. For luciferase assay, cells were transfected with appropriate reporter plasmids and
assayed as described below.
RNA isolation and quantitative real-time PCR
C4-2 and LNCaP cells were cultured in 5% charcoal stripped FBS RPMI for 24 hours and then
transfected with either siControl (40 pmol/mL) or siPABPC1 (40 pmol/mL) for 48 hours fol-
lowed by treatment with DMSO or 0.1nM R1881 for an additional 24 hours. RNA was isolated
from subconfluent cells using Trizol (Life Technologies, Carlsbad, CA) followed by phenol
chloroform extraction. Following quantitation, 1μg of RNA was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA).
qRT-PCR was performed using Taqman Universal Master Mix (Applied Biosystems, Carlsbad,
CA) with either Taqman primers specific for PABPC1 (Hs01598422_mH) or primers/probes
spanning exon/exon junctions designed using Primer 3 software (Primer 3, Totowa, NJ):
GAPDH For: 5’-CAT GTT CGT CAT GGG TGT GA-3’; Rev: 5’-GGT GCT AAG CAG TTG
GTG GT-3’; Probe: 5’-6FAM ACA GCC TCA AGA TCA TCA GCA ATG CCT C TAMRA-3’
and PSA For: 5’-CAT CAG GAA CAA AAG CGT GA-3’; Rev: 5’-AGC TGT GGC TGA CCT
GAA AT-3’; Probe: 5’-6FAM CAC AGC CTG TTT CAT CCT GAA GAC ACA TAMRA-3’.
The comparative Ct method [17] was used to analyze gene expression differences between con-
trol (untreated) cells and cells treated with R1881.
BrdU cell proliferation assay
C4-2, LNCaP, PC3, and 22Rv1 cells were transfected with siPABPC1 (40 pmol/mL) or control
siRNA (40 pmol/mL) for 72 hours followed by addition of BrdU (Sigma Aldrich, St Louis,
MO) for 1 hour at 37°C. Cells were then fixed with Carnoy’s fixative (3 vol methanol + 1 vol
glacial acetic acid), incubated with 2M HCl, washed with 0.1M boric acid, followed by incuba-
tion with 3% H202. After blocking with 10% goat serum, cells were incubated with anti-BrdU
antibody (Sigma Aldrich, St Louis, MO) overnight, followed by addition of Cy3 secondary anti-
body (Life Technologies, Grand Island, NY). Cells were visualized with a Nikon Eclipse TE
2000-U fluorescence microscope (Nikon Instruments, Inc., Melville, NY). Images were taken at
100x total magnification and all BrdU positive cells were counted in each image. The mean
average of three experiments from cells transfected with control siRNA was compared to cells
transfected with siPABPC1.
Luciferase reporter assay
To determine the effect of PABPC1 knockdown on PSA promoter activity, siControl oligos or
oligos specific for PABPC1 were transfected with PSA6.1 luc and pRL-CMV renilla plasmids
into C4-2 cells using Lipofectamine 2000. After 24–48 hours cells were lysed and luciferase
activity was measured on an LmaxII384 luminometer (Molecular Devices, Sunnyvale, CA)
using a Promega luciferase assay kit (Promega, Sunnyvale, CA) following the manufacturer’s
recommendations. The PSA6.1 firefly luciferase activity was normalized to pRL-CMV renilla
luciferase activity. For hormone induction, cells were cultured in 5% charcoal stripped FBS
RPMI for 24 hours followed by treatment with 0.1nM R1881 for an additional 24 hours. All
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experiments were done in triplicate and repeated at least three times. Significance was deter-
mined by Student’s t-test using GraphPad Prism software (San Diego, CA).
Results
Identification of AR50-250 target proteins
The NTD of the AR plays a key role in AR transactivation including androgen-independent
activation of the AR in castration-resistant prostate cancer (CRPC) cells. Thus, identification
of binding partners of the NTD is crucial to the design of specific therapies targeting this
region. Recently, our group found that the region of amino acids 50–250 (AR50-250) of the
NTD can promote cytoplasmic localization of the AR [12]. To determine proteins interacting
with AR50-250, GFP pull-down was performed followed by MALDI TOF/TOF mass spectrome-
try analysis. MALDI TOF/TOF data was analyzed for protein identification with ABSciex Pro-
tein Pilot 3.0 using Mascot (version 2.1.0). Searches used the IPI_human_3.68 human (87061
sequences; 35160944 residues) protein database. This led to the identification of proteins as
potential interacting partners with the region of a.a. 50–250 of the NTD of the AR (S1 Table).
Protein scores were derived from ion scores as a non-probabilistic basis for ranking protein
hits. Protein scores greater than 62 were considered to be significant (p<0.05). One protein
identified was poly (A) binding protein cytoplasmic 1 (PABPC1) (S2 Table). PABPC1 was
shown to have the highest score and appears to be a novel interacting partner of the AR and
was thus investigated further.
Up-regulation of PABPC1 in prostate cancer correlates to increased
disease recurrence
To explore the expression of PABPC1 in prostate tumors, in silico analysis was performed
using Oncomine [18]. Multiple studies [19–22] showed that PABPC1 was up-regulated in
prostate cancer specimens compared with normal controls (Table 1). Additionally, analysis of
the MSKCC cBioPortal for Cancer Genomics database showed that PABPC1 was up-regulated
in 44 of 216 (20%) tumor samples [23–25]. In the MSKCC cohort, patients with up-regulation
of PABPC1 were shown to have increased disease recurrence (Fig 1). Up-regulation of
PABPC1 significantly shortened the time to disease recurrence to only 64 months disease free
with up-regulated PABPC1 from 110 months disease free without increased expression of
PABPC1 (Fig 1). This suggests a significant role for PABPC1 in prostate carcinogenesis.
Table 1. In silico analysis of the Oncomine database revealed that PABPC1 is up-regulated in prostate
cancer tumor samples.
Research study Study size
(n)
PABPC1 up-regulation in PrCa tumors (Fold
change)
p-
value
Singh et al., Cancer cell
2002
235 2.288 8.92E-
6
Yu et al., J Clin Oncol 2004 152 1.644 3.83E-
6
Vanaja et al., Cancer Res
2003
28 1.576 2.06E-
5
Luo et al., Mol Carcinog
2002
30 1.364 8.11E-
4
doi:10.1371/journal.pone.0128495.t001
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PABPC1 is expressed in both AR-positive and AR-negative prostate
cancer cells
Prostate cancer cells (PC3, C4-2, LNCaP, and 22Rv1) and normal prostate stromal fibroblasts
(WPMY-1) were examined to determine the relative expression levels of PABPC1 (Fig 2A).
Western blot analysis showed that PABPC1 is expressed in all the tested cells with slightly
higher expression in AR-positive prostate cancer cells (Fig 2B).
PABPC1 interacts with the NTD of the AR
To confirm the interaction of PABPC1 with AR50-250 detected by mass spectrometry, co-
immunoprecipitation was performed. C4-2 cells were transiently transfected with AR deletion
mutants tagged with GFP (Fig 3A) followed by immunoprecipitation with anti-GFP beads. As
shown, PABPC1 formed a complex with AR50-250 (Fig 3B). In addition, using C4-2 cell lines
stably transfected with GFP-AR50-250, AR1-293, and AR294-556, it was shown that PABPC1 binds
to both GFP-AR50-250 and GFP-AR1-293 (Fig 3C). To demonstrate that PABPC1 and full length
AR interact, C4-2 cells were transiently transfected with GFP or GFP-AR followed by GFP
Fig 1. Up-regulation of PABPC1 correlates with increased disease recurrence. In silico analysis of the MSKCC cBioPortal for Cancer Genomics
database for prostate adenocarcinoma was performed for PABPC1. Kaplan Meier plot of the risk of disease recurrence for patients with up-regulation in
PABPC1 compared to patients without any alterations in PABPC1 is shown (23, 24).
doi:10.1371/journal.pone.0128495.g001
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pull-down assay (Fig 3D). These results suggested that PABPC1 and the AR form a complex
and that PABPC1 interacts specifically with the AR50-250 region.
PABPC1 knockdown inhibits AR transactivation of the androgen
responsive gene PSA
The AR is a ligand dependent transcription factor known to bind to androgen response ele-
ments (AREs) and activate transcription of androgen responsive genes such as PSA [26],
Nkx3.1[27], and VEGF [28]. Since PABPC1 was shown to interact with the AR, we next exam-
ined the effects of knockdown of PABPC1 on AR transactivation using siRNA. C4-2 cells were
transfected with control siRNA or siRNA (pool of three oligos) specific for PABPC1. Knock
down of PABPC1 significantly suppressed androgen induction of PSA luciferase activity more
than 80% compared to control siRNA (Fig 4A). This was confirmed by western blot analysis,
which also showed inhibition of androgen induced PSA protein levels when PABPC1 was
knocked down (Fig 4B). Additionally, knock down of PABPC1 suppressed PSA protein levels
and luciferase in complete media (10% FBS RPMI) (Fig 4C and 4D). Similar results were seen
with the individual oligos from the pool of PABPC1 siRNA oligos, indicating that this effect
was not due to non-specific targeting of the siRNAs (Fig 4E). These results suggested that
PABPC1 is a novel co-regulator of the AR in prostate cancer cells.
Knockdown of PABPC1 inhibits activation of the PSA promoter by NAR
(AR lacking LBD)
Recently, splice variants of the androgen receptor lacking the LBD have been shown to activate
transcription of androgen response genes [29,30]. Here, an AR mutant construct lacking the
entire LBD region, NAR, (Fig 5A) was transfected into C4-2 cells that were pretreated with
siRNA specific for PABPC1 to determine if PABPC1 could regulate the up-regulation of andro-
gen response genes by AR variants. Indeed, this was the case as knockdown of PABPC1 vastly
decreased the activation of the PSA promoter (Fig 5B). This result along with the previous
result of PABPC1 interacting with the NTD of the AR, suggests that PABPC1 could be binding
to the NTD of the AR and blocking activation of androgen response genes through inhibition
of the AR and its splice forms lacking the LBD.
Fig 2. PABPC1 is expressed in prostate cancer cells. (A) Prostate cancer cell lines (PC3, LNCaP, C4-2, and 22Rv1) and normal prostate cells (WPMY-1)
were analyzed byWestern blot for protein expression levels of PABPC1 (Santa Cruz). (B) Expression levels of the AR in C4-2, LNCaP, and 22Rv1 cell lines.
GAPDH (Santa Cruz) was used as a loading control. The numbers indicate the relative expression of PABPC1 or AR quantitated using ImageJ software
when normalized to GAPDH.
doi:10.1371/journal.pone.0128495.g002
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Reduction of nuclear AR by PABPC1 knockdown
To determine the effect of inhibition of PABPC1 expression on AR nucleocytoplasmic traffick-
ing, C4-2 cells were transfected with siPABPC1 for 48 hours followed by treatment with 0.1nM
R1881 or vehicle for an additional 24 hours. Western blot analysis of nuclear and cytoplasmic
fractions revealed that nuclear AR protein levels were reduced with the knockdown of
PABPC1 in C4-2 cells (Fig 6A). Additionally, hormone induction of PSA mRNA levels in both
LNCaP (Fig 6B) and C4-2 cells (Fig 6C) was significantly reduced by knockdown of PABPC1
(Fig 6D and 6E). Another androgen response gene, FKBP5, was tested for specificity of
PABPC1 to androgen response gene expression. Inhibition of PABPC1 was shown to decrease
the androgen up-regulation of FKBP5 by R1881 (S1 Fig). These results suggest that PABPC1
controls the amount of the AR in the nucleus and plays a role in the transactivation of AR tar-
get genes in these cell lines.
Suppression of PABPC1 inhibits AR-positive prostate cancer cell
proliferation
To determine the effect of PABPC1 on prostate cancer cell proliferation, siRNA specific for
PABPC1 knockdown was transfected into C4-2, LNCaP, PC3, and 22Rv1 cells. Knockdown
efficiency was determined by Western blot (S2 Fig). AR-positive C4-2, LNCaP, and 22Rv1 cells
Fig 3. PABPC1 forms a complex with AR50-250 in C4-2 cells. (A) Schematic diagram of GFP-tagged AR (GFP-AR) and its deletion mutants, GFP-AR(1–
293), GFP-AR(294–556) and GFP-AR(50–250). The numerical numbers indicate positions of a.a. of the AR. (B) C4-2 cells were transiently transfected with GFP or
GFP-AR50-250 followed by GFP pull-down. Western blot analysis was performed using antibodies specific for PABPC1 (Santa Cruz) and GFP (Torrey Pines
Biolabs). (C) Immunoprecipitation was performed with GFP beads using C4-2 cells stably transfected with GFP, GFP-AR(1–293), GFP-AR(50–250), or
GFP-AR(294–556). Western blot analysis was performed as in (B). (D)GFP or GFP-AR was transiently transfected into C4-2 cells and lysates were
immunoprecipitated using GFP conjugated beads followed by western blot analysis as in (B). Experiments were reproduced three times.
doi:10.1371/journal.pone.0128495.g003
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exhibited significantly less proliferation upon PABPC1 knockdown when compared to control
cells (Fig 7). In contrast, AR-negative PC3 cell proliferation was not affected by PABPC1
knockdown. This suggested that PABPC1 plays a role in the proliferation of AR-positive pros-
tate cancer cells including castration-resistant C4-2 cells.
Discussion
The AR plays a major role in all stages of prostate cancer development and progression, includ-
ing CRPC, thus it is important to determine the mechanisms involved including the impact of
AR co-regulators. This study identified PABPC1 as a novel AR co-regulator capable of modu-
lating AR function and subcellular localization in prostate cancer cells. PABPC1 is associated
with the AR through the NTD region (AR50-250) that can promote AR cytoplasmic localization.
Fig 4. Knockdown of PABPC1 with siRNA decreases PSA luciferase activity and PSA protein levels. (A) C4-2 cells were transfected with control
siRNA (siC) (40 pmol/mL), siPABPC1 (pool of 3 oligos) (40 pmol/mL), pRL-CMV (0.03μg), and PSA6.1Luc (0.3μg) in OPTI-MEM. The media was changed
the next day to 5% chS FBS RPMI for 24 hours followed by treatment with 0.1nM R1881for an additional 24 hours in 5% chS FBS RPMI. Luciferase assay
was performed with pRL-CMV (Renilla) luciferase used as a normalizer. (B) C4-2 cells were transfected with control siRNA (siC) or siPABPC1 (40 pmol/mL)
and treated as in (A) using increasing doses of R1881 (0, 0.1, and 1nM) followed byWestern blot analysis. Blots were probed with antibodies specific for
PABPC1 and PSA. GAPDH was used as a loading control. (C) C4-2 cells were transfected with control siRNA (siC) or siPABPC1 (pool of 3 oligos) (20 pmol/
mL, 40 pmol/mL and 80 pmol/mL), in OPTI-MEM. Media was changed the next day to 10% FBS RPMI for 72 hours followed byWestern blot analysis. Blots
were probed as in (B). C4-2 cells were transfected with control siRNA (siC) or siPABPC1 (pool of 3 oligos) (40 pmol/mL), (D) or individual PABPC1 siRNA
oligos (E), pRL-CMV (0.03μg), and PSA6.1Luc (0.3μg) in OPTI-MEM. The media was changed the next day to 10% FBS RPMI for an additional 48 hours
followed by luciferase assay. Experiments were repeated three times. Significance was determined by Student’s t-test (*p<0.05, **p<0.01, ***p<0.001).
doi:10.1371/journal.pone.0128495.g004
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Knockdown of PABPC1 decreased AR transcriptional activity and also reduced nuclear AR in
C4-2 prostate cancer cells. Furthermore, PABPC1 knockdown inhibited proliferation of all the
tested AR-positive but not the AR-negative PC3 prostate cancer cells. In silico analysis of sev-
eral publicly available datasets including the MSKCC cBioPortal for Cancer Genomics database
revealed PABPC1 up-regulation in prostate cancer specimens and this up-regulation was asso-
ciated with rapid disease recurrence. These findings suggest a significant role for PABPC1 in
modulating AR activity and prostate carcinogenesis.
PABPC1 appears to play important roles in AR function in both androgen-sensitive and
castration-resistant prostate cancer cells. In both androgen-sensitive LNCaP and castration-
resistant C4-2 cells, PABPC1 knockdown reduced PSA-based luciferase activity as well as
inhibited the expression of endogenous PSA mRNA and protein. These findings suggest that
PABPC1 up-regulation in prostate cancer cells can enhance androgen signaling and subse-
quently promote prostate cancer cell proliferation in both androgen-sensitive and castration-
resistant stages of the disease.
PABPC1 appears to inhibit AR nuclear export and/or enhance AR nuclear import, because
PABPC1 knockdown decreased endogenous nuclear AR protein levels in C4-2 cells. The mod-
ulation of AR subcellular localization by PABPC1 is likely mediated through AR50-250 (a region
in the NTD capable of promoting AR cytoplasmic localization) because PABPC1 is associated
with this region in co-immunoprecipitation assays. Since AR50-250 promotes AR cytoplasmic
localization using the CRM-1-dependent nuclear export pathway [12], the modulation of AR
Fig 5. Knockdown of PABPC1 inhibits activation of the PSA promoter by NAR. (A) Schematic diagram
of GFP-NAR. (B) C4-2 cells were transfected with control siRNA (siC) or siPABPC1 (pool of 3 oligos) (40
pmol/mL) for 48 hours followed by transfection with PSA6.1Luc, pRL-CMV, and either GFP (control) or
GFP-NAR in the presence of 5% charcoal stripped FBS RPMI for an additional 48 hours followed by
luciferase assay. Experiments were repeated two times. Significance was determined by Student’s t-test
(**p<0.01, ***p<0.001).
doi:10.1371/journal.pone.0128495.g005
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Fig 6. Knockdown of PABPC1 with siRNA decreases nuclear AR protein levels and PSAmRNA expression levels. (A) C4-2 cells were transfected
with control siRNA (siC) (40 pmol/mL) or siRNA (40 pmol/mL) specific for PABPC1 (siPABPC1) for 48 hours followed by treatment with 0.1nMR1881 for 24
hours in the presence of 5% charcoal-stripped FBS RPMI. Nuclear and cytoplasmic extracts were analyzed byWestern blot. GAPDH (Santa Cruz) and
Lamin A/C (Genscript, Piscataway, NJ) were used as loading and cell compartment controls. PSA (B-C) and PABPC1 (D-E)mRNA expression levels were
detected in LNCaP and C4-2 cells following siPABPC1 treatment as in (A). Expression was normalized to GAPDH. Experiments were reproduced twice.
Significance was determined by Student’s t-test (**p<0.01, ***p<0.001).
doi:10.1371/journal.pone.0128495.g006
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subcellular localization by PABPC1 is likely mediated through this pathway as well. Our find-
ing also indicates that AR50-250 in the context of the full-length AR can modulate intracellular
trafficking via PABPC1 because PABPC1 association with AR is specifically mediated through
AR50-250.
PABPC1 modulation of the AR is likely to have a significant impact on prostate cancer pro-
gression because the AR is a key factor regulating prostate cancer cell growth and factors capa-
ble of modulating AR function could have profound effects in modulating prostate cancer cell
growth. We recognize that PABPC1 has the potential to modulate multiple signaling pathways.
As a poly A binding protein, it could influence translation of multiple signaling molecules.
However, its influence on prostate cancer cell growth is likely mediated through the AR
because PABPC1 knockdown inhibited proliferation of AR-positive prostate cancer cells, but
Fig 7. Inhibition of PABPC1 decreases proliferation of AR positive prostate cancer cells.C4-2, LNCaP, PC3, and 22Rv1 cells were transfected with
control siRNA (40 pmol/mL) or a pool of siPABPC1 oligos (40 pmol/mL) followed by BrdU assay (as described in the Methods section). (A) Shown are
representative images from three individual experiments of cells treated with either control siRNA (siC) or siPABPC1. (B) BrdU positive cells were counted
and compared between siC and siPABPC1 groups. Experiments were reproduced three times. Significance was determined by Student’s t-test. (*p<0.05,
**p<0.01).
doi:10.1371/journal.pone.0128495.g007
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not AR-negative PC3 cells. The up-regulated expression of PABPC1 in prostate cancer speci-
mens and the association of high-level PABPC1 expression with recurrent prostate cancer fur-
ther suggest that PABPC1 plays an important role in promoting prostate cancer progression.
Identification of PABPC1 as a co-factor of the AR provides a potential link between AR
activity and active translation in prostate cancer cells. PABPC1 is thought to stimulate efficient
mRNA cap-dependent translation. Thus, elevated PABPC1 expression levels in prostate cancer
cells can simultaneously enhance translation and androgen action, which may lead to more
efficient cell growth. As a CRM-1 dependent shuttling protein between nuclear and cyto-
plasmic regions [31,32], PABPC1 may modulate AR activity via regulating the nucleocytoplas-
mic trafficking of the AR. However, PABPC1 may influence AR activity via interaction with
other co-regulators of the AR. For example, PABPC1 can interact with paxillin [31,32], which
is also an AR co-factor [33]. Paxillin is capable of modulating AR nucleocytoplasmic trafficking
[33], suggesting that paxillin may facilitate or modulate the PABPC1 regulation of the AR.
Though, we cannot rule out the possibility that PABPC1 can modulate the stability of AR in
the nucleus.
In summary, the results of our present study suggest that PABPC1 is an important AR co-
regulator capable of promoting AR nuclear localization and function via interaction with the
NTD region. Elevated expression of PABPC1 in prostate cancer specimens is likely to play an
important role in prostate carcinogenesis by enhancing AR signaling pathways. Future studies
aimed at defining the precise mechanism of PABPC1 regulation of AR signaling may lead to
new approaches to prevent and/or treat prostate cancer patients.
Supporting Information
S1 Fig. Androgen induction of FKBP5 is reduced by inhibition of PABPC1. cDNA lysates
used in Fig 6 were assayed for expression of FKBP5 mRNA levels by real-time PCR.
(TIF)
S2 Fig. Efficiency of PABPC1 knockdown in prostate cancer cell lines. C4-2, LNCaP, 22Rv1,
and PC3 cells were transfected with siC or siPABPC1 for 72 hours followed by Western blot
analysis. Antibodies specific for PABPC1 and GAPDH were used to probe the blots as previ-
ously described.
(TIF)
S1 Table. Identification of interacting partners of a.a. 50–250 of the AR by mass spectrome-
try.
(TIF)
S2 Table. PABPC1 peptide bands interacting with a.a. 50–250 of the AR.
(TIF)
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